Universidad de Navarra
Organización
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublications in collaboration with researchers from Memorial Sloan Kettering Cancer Center (252)
2024
-
A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey
European Journal of Surgical Oncology, Vol. 50, Núm. 10
-
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell
-
Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial
International Journal of Gynecological Cancer
-
Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis
Science Advances , Vol. 10, Núm. 42
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer
International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 504-509
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Advances in Therapy, Vol. 41, Núm. 11, pp. 4125-4139
-
Epichaperome-targeted myocardial imaging by 124I-PU-H71 PET
Clinical and Translational Imaging
-
Factors Associated with and Impact of Open Conversion in Laparoscopic and Robotic Minor Liver Resections: An International Multicenter Study of 10,541 Patients
Annals of surgical oncology, Vol. 31, Núm. 9, pp. 5615-5630
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
Himalaya Overall Survival Prominence and Other Routes to the Peak
JAMA Oncology
-
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Blood
-
Impact of Liver Cirrhosis, Severity of Cirrhosis, and Portal Hypertension on the Difficulty and Outcomes of Laparoscopic and Robotic Major Liver Resections for Primary Liver Malignancies
Annals of Surgical Oncology, Vol. 31, Núm. 1, pp. 97-114
-
Impact of liver cirrhosis, severity of cirrhosis and portal hypertension on the difficulty of laparoscopic and robotic minor liver resections for primary liver malignancies in the anterolateral segments
European Journal of Surgical Oncology, Vol. 50, Núm. 1
-
Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study
European Journal of Surgical Oncology, Vol. 50, Núm. 6
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216